type here...

CATEGORIES

Pharmaceutics

LATEST

1...567...11Page 6 of 11

TRENDING

EDITORS CHOICE

Colchicine Shows 48% Reduction in Future Cardio Issues for Heart Attack Victims

Medika Life -
Early, in-hospital treatment with colchicine reduces the odds of future cardiovascular problems by 48% in people who have just survived a heart attack

SPRAVATO® (esketamine) CIII Nasal Spray to Treat Depressive Symptoms in Adults Approved

Medika Life -
SPRAVATO® (esketamine) CIII nasal spray, taken with an oral antidepressant, to treat depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior.

Tech Marches On, While Humanity Drags Its Feet

John Nosta -
I thought it would be fun to look back at some of my predictions for health tech from almost a decade ago in Forbes....

FDA Approves Drug Combination for Treating Mesothelioma

Medika Life -
First approval in 16 years for mesothelioma, a type of cancer caused by inhaling asbestos fibers SILVER SPRING, Md., Oct. 2, 2020 /PRNewswire/ -- Today, the U.S. Food...

CONNECT WITH US ON SOCIAL MEDIA

Medika Life is a unique, not-for-profit operating unit of FINN Partners and maintains an independent voice. Authors opinions may not necessarily represent those shared by FINN Partners and content cannot be promotional - rather informational centered on health issues, life science innovation, ecohealth and patient experience.

© Medika Life 2020 - 2022

Compliance

CORPORATE & MEDIA

Popular categories